Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | LAP3 | P28838 | 9/20 | 0.47 |
| ▸ | ANPEP | P15144 | 7/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.37 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.37 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28734812 | 0.83 | SLC7A5 (0.44) | SLC7A5LAP3ANPEPERAP1SLC1A3 | |
| SCHEMBL28734807 | 0.80 | SLC7A5 (0.41) | SLC7A5LAP3ANPEPERAP1SLC1A3 | |
| Phosphoric Acid SCHEMBL28734814 | 0.80 | SLC7A5 (0.48) | SLC7A5LAP3ANPEPERAP1SLC1A3 | |
| SCHEMBL29761147 | 0.79 | SLC7A5 (0.44) | SLC7A5LAP3ANPEPERAP1SLC1A3 | |
| Phosphoric Acid SCHEMBL28734810 | 0.78 | SLC7A5 (0.47) | SLC7A5LAP3ANPEPERAP1SLC1A3 | |
| SCHEMBL771739 | 0.78 | CA4 (0.39) | CA4 | |
| SCHEMBL28355439 | 0.78 | CA4 (0.44) | CA4 | |
| SCHEMBL771737 | 0.78 | CA4 (0.39) | CA4 | |
| SCHEMBL771738 | 0.78 | CA4 (0.39) | CA4 | |
| SCHEMBL9807834 | 0.78 | CA4 (0.39) | CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382625-A1 | INDICATOR COMPOUNDS, DEVICES COMPRISING INDICATOR COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | WILLOW LABORATORIES INC (US) | 2024-11-21 | — | — | US | disclosed |
| US-11951186-B2 | Indicator compounds, devices comprising indicator compounds, and methods of making and using the same | WILLOW LABORATORIES, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| CN-115176155-A | Indicator compounds, devices including indicator compounds, and methods of making and using the same | 塞卡科实验室有限公司 | 2022-10-11 | — | — | CN | disclosed |
| EP-4049032-A1 | INDICATOR COMPOUNDS, DEVICES COMPRISING INDICATOR COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | Cercacor Laboratories, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| WO-2021081404-A1 | INDICATOR COMPOUNDS, DEVICES COMPRISING INDICATOR COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | CERCACOR LABORATORIES, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| US-20210121582-A1 | INDICATOR COMPOUNDS, DEVICES COMPRISING INDICATOR COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | MASIMO LABORATORIES | 2021-04-29 | — | — | US | disclosed |
| US-10975119-B2 | Selective cysteine protease inhibitors and uses thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2021-04-13 | — | — | US | disclosed |
| US-20180186833-A1 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | GENESIS TECH LIMITED (BB) | 2018-07-05 | — | — | US | disclosed |
| US-9944674-B2 | Selective cysteine protease inhibitors and uses thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2018-04-17 | — | — | US | disclosed |
| EP-2697246-B1 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | GENESIS TECH LIMITED (BB) | 2018-03-07 | — | — | EP | disclosed |
| WO-2012140500-A1 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES, INC. (CA) | 2012-10-18 | — | — | WO | disclosed |
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES, INC. (CA) | 2012-06-21 | — | — | US | disclosed |
| WO-2010133000-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES INC. (CA) | 2010-11-25 | — | — | WO | disclosed |
| US-6133000-A | CONTINUOUS FEEDING OF CORYNEBACTERIUM CULTURE TO PRODUCE L-LYSINE | DEGUSSA-HULS AKTIENGESELLSCHAFT (DE) | 2000-10-17 | — | — | US | disclosed |
| US-5770409-A | CONTINUOUSLY SUPPLYING SUCROSE OR GLUCOSE | DEGUSSA AKTIENGSELLSCHAFT (DE) | 1998-06-23 | — | — | US | disclosed |
| CN-1038693-C | Process for the fermentative preparation of amino acids | DEGUSSA (DE) | 1998-06-10 | — | — | CN | disclosed |
| CN-1070687-A | Process for the fermentative preparation of amino acids | DEGUSSA (DE) | 1993-04-07 | — | — | CN | disclosed |
| US-5133976-A | Biosynthesis | RHONE-POULENC SANTE (FR) | 1992-07-28 | — | — | US | disclosed |
| EP-0160794-B1 | CHICKEN FLAVORANTS AND THE PROCESSES FOR PREPARING THEM | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 1988-06-29 | — | — | EP | disclosed |
| EP-0160794-A1 | Chicken flavorants and the processes for preparing them | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 1985-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP1, VIP, CASP5 | SLC7A5 3433/4885LAP3 877/4885ANPEP 396/4885 |
| US-20180186833-A1 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | SERPINB1, SERPINE1, CASP5 | SLC7A5 1444/4885LAP3 721/4885ANPEP 667/4885 |
| US-10975119-B2 | Selective cysteine protease inhibitors and uses thereof | SERPINB1, SERPINE1, CASP5 | SLC7A5 1343/4885LAP3 586/4885ANPEP 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.